STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Short Interest Update

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) was the recipient of a significant drop in short interest in September. As of September 15th, there was short interest totalling 2,600 shares, a drop of 25.7% from the August 31st total of 3,500 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 24,800 shares, the short-interest ratio is presently 0.1 days.

STRATA Skin Sciences Stock Down 7.8 %

SSKN opened at $2.95 on Friday. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.14 and a quick ratio of 0.92. The company’s 50-day moving average is $3.13 and its 200 day moving average is $3.69. STRATA Skin Sciences has a fifty-two week low of $2.51 and a fifty-two week high of $7.10. The firm has a market capitalization of $10.35 million, a P/E ratio of -0.89 and a beta of 1.37.

STRATA Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings results on Wednesday, August 14th. The medical device company reported ($0.03) earnings per share for the quarter. STRATA Skin Sciences had a negative net margin of 25.40% and a negative return on equity of 50.45%. The firm had revenue of $8.44 million for the quarter. Research analysts expect that STRATA Skin Sciences will post -1 earnings per share for the current fiscal year.

Insider Buying and Selling at STRATA Skin Sciences

In other STRATA Skin Sciences news, Director Uri Geiger acquired 230,573 shares of the company’s stock in a transaction on Monday, July 15th. The shares were purchased at an average cost of $3.14 per share, with a total value of $723,999.22. Following the completion of the purchase, the director now owns 1,441,835 shares of the company’s stock, valued at $4,527,361.90. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other STRATA Skin Sciences news, Director Uri Geiger acquired 230,573 shares of the company’s stock in a transaction on Monday, July 15th. The shares were purchased at an average cost of $3.14 per share, with a total value of $723,999.22. Following the completion of the purchase, the director now owns 1,441,835 shares of the company’s stock, valued at $4,527,361.90. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Dolev Rafaeli purchased 19,100 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were purchased at an average cost of $3.14 per share, for a total transaction of $59,974.00. Following the completion of the transaction, the chief executive officer now directly owns 143,156 shares of the company’s stock, valued at $449,509.84. The disclosure for this purchase can be found here. Insiders own 40.43% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in STRATA Skin Sciences stock. Azzad Asset Management Inc. ADV increased its stake in shares of STRATA Skin Sciences, Inc. (NASDAQ:SSKN) by 289.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 67,000 shares of the medical device company’s stock after buying an additional 49,800 shares during the period. Azzad Asset Management Inc. ADV owned about 0.19% of STRATA Skin Sciences worth $25,000 as of its most recent SEC filing. 32.43% of the stock is currently owned by hedge funds and other institutional investors.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.